Sierra Oncology’s corporate headquarters are located in Vancouver, Canada.
2150-885 West Georgia Street
Vancouver, British Columbia
Canada V6C 3E8
Phone: (604) 558-6536
Sierra Oncology’s clinical development team is primarily located in our San Francisco area office.
For media inquiries, please send an email to email@example.com.
You can view our recent press releases by visiting the Investor section of our website.
Electronic copies of our Annual Report and other periodic reports, are available in the Financial Reporting section in the Investor Section of our corporate website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.
You must send both your old and new addresses to our transfer agent, American Stock Transfer, http://www.amstock.com/main/nav_contactUs.asp, by mail. Each stockholder in question must sign the request for an address change.
There is no need to replace lost stock certificates. Following Sierra Oncology’s initial public offering, all physical stock certificates were deemed void and the shares represented by the stock certificates were reflected in an electronic book entry account set up for you with our transfer agent, American Stock Transfer (AST). For questions about how many shares you hold, please contact AST at: http://www.amstock.com/main/nav_contactUs.asp. AST can look up your records and provide information about your shares.
Sierra Oncology was incorporated in Delaware in May 2003 as Phenome Systems, Inc. and our name was changed to Sierra Oncology, Inc. in January 2017.
Sierra Oncology’s CUSIP number is 82640U107.
Sierra Oncology has never declared or paid cash or stock dividends on its common stock. Sierra Oncology anticipates to retain all available funds and any future earnings, if any, for use in the operation of its business and does not anticipate paying dividends in the foreseeable future.
Sierra Oncology does not offer a direct stock purchase plan.
Shares can be purchased through a stockbroker of your choice.
Deloitte & Touche LLP is Sierra Oncology’s independent registered public accounting firm.
Sierra Oncology’s fiscal year-end is December 31.
You can view our Board of Directors by visiting the Directors section of our website.
Sierra Oncology’s transfer agent is American Stock Transfer and Trust Company, LLC (AST). You can find more information about how to contact AST at: http://www.amstock.com/main/nav_contactUs.asp.
You can view our management team by visiting the Leadership section of our website.
Sierra Oncology’s common stock is traded on the NASDAQ Global Market under the ticker symbol “SRRA”.
Sierra Oncology’s initial public offering was on July 16, 2015.
Please visit the Investor Alerts section of our corporate website.